Increasing Productivity and Profitability

Biologics

Commercial Thinking Begins in Clinical Phases

Mathias Kahl

IDT Biologika

Partner Selection

How are organizations balancing cost with regulatory, supply chain, and reputational risk when selecting partners or sites?

Pharma's Almanac

Potency Assurance

Why Potency Cannot Be Reduced to a Release Assay in Active Immunotherapy Development

David Alvaro, Ph.D.

Pharma's Almanac

Preparedness

Preparing Manufacturing Networks for the Next Pandemic

Pharma's Almanac

Supply Chain

Supply Chain Resilience in 2026: Any Progress?

Cynthia A. Challener, Ph.D.

Pharma's Almanac

ATMP Supply Chain

Maintaining Resilient Supply Chains for Advanced Therapies

Pharma's Almanac

Thermostable Vaccine

Thermostable Vaccines and the Future of Global Distribution

David Alvaro, Ph.D.

Pharma's Almanac

Device Integration

Medical Device Integration: Exploring the Benefits and Challenges to Effective Implementation

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Supply Chain

Supply Chain Resilience Is Not an Insurance Cost, but Value Protection

Anurag Bhagania

OneSource Specialty Pharma

Critical Materials

Securing Critical Materials for Resilient Biopharmaceutical Manufacturing

Pharma's Almanac

Geopolitics

How are geopolitical factors influencing sourcing and manufacturing decisions for 2026 and beyond?

Pharma's Almanac

Stem Cells

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac